At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency ...
The messenger RNA (mRNA)–based vaccines BNT162b2 and mRNA-1273 are more than 90% effective against coronavirus disease 2019 (Covid-19). However, their comparative effectiveness for a range of outcomes ...
In the years after the 2020 COVID-19 pandemic, it is clear that mRNA as a modality for vaccines and therapeutics is here to stay based on the number of mRNA programs currently in clinical development.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results